Cognizant announced a major IT services deal with Gilead Sciences, a biopharmaceutical company, to manage Gilead’s IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation.
The agreement includes renewal and expansion of Cognizant services for a total expected value of $800 million over the next five years.
This collaboration is aimed at enabling Gilead to streamline various parts of its business with the goal of faster time to market of various medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer, Cognizant said.
Gilead has been working with Cognizant for more than three years to adopt cutting-edge technologies designed to drive better business outcomes. This includes supporting enabling technologies for running business operations, product launches and improving IT processes for efficient research, manufacturing, and commercialization of its products.
“Cognizant has provided critical expertise to progress our digital transformation journey while enabling stable, secure operations. This has allowed us to advance research and commercialization of transformative treatments for some of the world’s most challenging diseases,” said Marc Berson, Chief Information Officer at Gilead Sciences.
